Amyloid-beta globulomer antibodies

• US 8,497,072 B2
• Filed: 11/30/2006
• Issued: 07/30/2013
• Est. Priority Date: 11/30/2005
• Status: Active Grant

• Current Assignee: Abbvie Deutschland GmbH & Company KG (Abbvie Incorporated)
• Original Assignee: Abbott Laboratories
• Inventors: Hillen, Heinz, Barghorn, Stefan, Labkovsky, Boris, Ebert, Ulrich, Striebinger, Andreas R., Keller, Patrick
• Primary Examiner(s): Kemmerer, Elizabeth C
• Assistant Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US11/574,847
• Publication Number:
  US 20090238831A1
• Time in Patent Office: 2,434 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/20 characterized by taxonomic origin
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2333/4709 Amyloid plaque core protein
• CPC Class Codes: G01N 2500/20 cell-free systems
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 33/577 involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens; G01N33/53 - G01N33/576 take precedence
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer'"'"'s Disease or other neurodegenerative disorders.

Claims

1. A hybridoma having American Type Culture Collection designation number PTA-7407.

2. A monoclonal antibody (8C5) produced by said hybridoma of claim 1.

3. A monoclonal antibody comprising a variable heavy chain encoded by SEQ ID NO:

11, wherein the antibody binds amyloid beta globulomer.

4. The monoclonal antibody of claim 3 wherein said antibody is human or humanized.

5. A monoclonal antibody comprising a variable light chain encoded by SEQ ID NO:

12, wherein the antibody binds amyloid beta globulomer.

6. The monoclonal antibody of claim 5 wherein said antibody is human or humanized.

7. The monoclonal antibody of claim 5 further comprising a variable light chain encoded by SEQ ID NO:

11.

8. The monoclonal antibody of claim 7 wherein said antibody is human or humanized.

9. A monoclonal antibody comprising SEQ ID NO:

19, wherein the antibody binds amyloid beta globulomer.

10. The monoclonal antibody of claim 9 wherein said antibody is human or humanized.

11. A monoclonal antibody comprising SEQ ID NO:

20, wherein the antibody binds amyloid beta globulomer.

12. The monoclonal antibody of claim 11 wherein said antibody is human or humanized.

13. A monoclonal antibody comprising a variable light chain and a variable heavy chain, wherein said variable heavy chain comprises complementarity determining regions (CDRs) of SEQ ID NO:

13, SEQ ID NO;

14 and SEQ ID NO;

15, wherein said variable light chain comprises CDRs of SEQ ID NO;

16, SEQ ID NO;

17 and SEQ ID NO;

18, and wherein the antibody binds amyloid beta globulomer.

14. A composition comprising the monoclonal antibody of claim 2 or claim 13.

15. A vaccine comprising the monoclonal antibody of claim 2 or claim 13 and a pharmaceutically acceptable adjuvant.

16. A kit comprising:

a) the monoclonal antibody of claim 2 or claim 13 and b) a conjugate comprising an antibody attached to a signal-generating compound, wherein said antibody of said conjugate is different from said monoclonal antibody.

17. A method of diagnosing Alzheimer'"'"'s Disease in a patient suspected of having this disease, comprising the steps of:

a. isolating a biological sample from said patient;

b. contacting said biological sample with the monoclonal antibody of claim 2 or claim 13 for a time and under conditions sufficient for formation of antigen/antibody complexes; and

c. detecting the presence of said antigen/antibody complexes in said sample, the presence of said complexes indicating a diagnosis of Alzheimer'"'"'s disease in said patient.

18. The method of claim 17, wherein said antigen is amyloid beta globulomer.